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national data from a small number of sites can be misleadingWe read with interest the results of the European component of the
RegionalResistanceSurveillance studyreportedby Jonesandcolleagues in
their online article on October 14, 2013 (Jones et al., 2013). This article
presents antimicrobial susceptibility test results from a collection of
European bacterial isolates with centralised determination of MICs for a
large panel of antibiotics, followed by interpretation according to 2
international breakpoint deﬁnitions. The authors suggest that the results
can be used to validate results from national and regional antimicrobial
resistance surveillance programs, such as the European Antimicrobial
Resistance Surveillance Network (EARS-Net) (ECDC, 2013).
Unfortunately, 2 important factors were not taken into account by
the authors, which preclude the use of their results for validation
purposes or to properly reﬂect the heterogeneous resistance situation
in Europe. Firstly, the results were based on pooled data from only 47
hospitals in 21 countries. Secondly, the authors mentioned large
variations in resistance percentages between countries, but these
inter-country differences were neither thoroughly presented, nor
discussed. As a consequence, the pooled estimates could be subject to
bias due to poor representativeness and might not reﬂect the true
picture of antimicrobial resistance in Europe.
Results from EARS-Net, based on routine microbiological data from
approximately 1300 hospitals in Europe, have repeatedly shown that
differences in antimicrobial resistance percentages between countries are
substantial. As an example, the national percentage of invasive Klebsiella
pneumoniae isolates resistant to third-generation cephalosporins varied
between 2% and 75% among the 30 European countries that participated
in EARS-Net in 2012. Similar signiﬁcant inter-country differences can be
found for many antimicrobial-microorganism combinations in the
publicly available on-line EARS-Net database (ECDC, 2014).
As the authors state in their conclusions, antimicrobial resistance
surveillance programs should be more widely supported to monitor
emerging resistance trends and follow the impact of structured
interventions at national, regional, and local levels. Moreover,
although European readers may be tempted to use the data provided
by the European component of the Regional Resistance Surveillance
study to update their guidelines for empiric therapy of infected
patients, due to the aforementioned limitations, much caution should
be exercised in doing so. While national antimicrobial resistance data
remain essential to describe the magnitude and trends in antimicro-
bial resistance in and between European countries, large variations
may exist even within 1 single country (Carbonne et al., 2013;
SWEDRES-SVARM, 2013; ECDC, 2013). It is, therefore, necessary for
hospitals and physicians to be familiar with their local surveillance0732-8893/© 2014 The Authors. Published by Elsevier Inc. This is an open access article udata and use them as a basis for the creation of local guidelines as well
as for empiric antimicrobial treatment of infections.
The Regional Resistance Surveillance study is indeed complemen-
tary to other surveillance programs such as EARS-Net and should, in
principle, provide additional, useful information. This goal, however,
is only partially achieved by this study due to the small number of
participating sites and the fact that the pooled data at the regional
level provide misleading information on antimicrobial resistance
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